Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in HER2-negative Breast Cancer.
This prospective study evaluated the imaging performance of a novel pretargeting immunologic PET (immuno-PET) method in patients with human epidermal growth factor receptor 2 (HER2)-negative, carcinoembryonic antigen (CEA)-positive metastatic breast cancer, compared with CT, bone MRI, and 18F-FDG PET.
- Ref: doi: 10.2967/jnumed.119.236000
- Année de publication : 2020
- Auteurs : Rousseau C, Goldenberg DM, Colombie M, Sebille JC, Meingan P, Ferrer L, Baumgartner P, Cerato E, Masson D, Campone M, Rauscher A, Fleury V, Labbe C, Faivre-Chauvet A, Frenel JS, Toquet C, Barbet J, Sharkey RM, Campion L, Kraeber-Bodere F.
- Réseaux : Réseaux: « Vectorisation, Imagerie, Radiothérapies » & « Cancers des Tissus Hormono-dépendants »